Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study
- PMID: 18407790
- DOI: 10.1016/S1470-2045(08)70103-7
Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study
Abstract
Background: The invasive potential of cervical intraepithelial neoplasia 3 (CIN3; also termed stage 0 carcinoma) has been poorly defined. At the National Women's Hospital, Auckland, New Zealand, treatment of CIN3 was withheld from a substantial number of women between 1965 and 1974 as part of an unethical clinical study. The resulting variation in management allows comparison of the long-term risk of invasive cancer of the cervix in women whose lesion was minimally disturbed with those who had adequate initial treatment followed by conventional management. We aimed to estimate the long-term risk of invasive cancer in these two groups of women. A judicial inquiry referred for independent clinical review in 1988 all women for whom there remained doubt about the adequacy of their management.
Methods: Between February, 2001, and December, 2004, medical records, cytology, and histopathology were reviewed for all women with CIN3 diagnosed between 1955 and 1976, whose treatment was reviewed by judicial inquiry and whose medical records could be located, and linkages were done with cancer and death registers and electoral rolls. To take into account the probability that the CIN3 lesion had been completely removed, we classified adequacy of treatment by type of procedure, presence of CIN3 at the excision margin, and subsequent cytology. The primary outcome was cumulative incidence of invasive cancer of the cervix or vaginal vault. Follow-up continued until death or Dec 31, 2000, whichever came first. Analyses accounted for procedures during follow-up.
Findings: 1229 women whose treatment was reviewed by the judicial inquiry in 1987-88 were included. Of these, 48 records (4%) could not be located and 47 women (4%) did not meet the inclusion criteria. At histopathological review, a further 71 (6% of 1134) women were excluded because the review diagnosis was not CIN3. We identified outcomes in the remaining 1063 (86% of 1229) women diagnosed with CIN3 at the hospital in 1955-76. In 143 women managed only by punch or wedge biopsy, cumulative incidence of invasive cancer of the cervix or vaginal vault was 31.3% (95% CI 22.7-42.3) at 30 years, and 50.3% (37.3-64.9) in the subset of 92 such women who had persistent disease within 24 months. However, cancer risk at 30 years was only 0.7% (0.3-1.9) in 593 women whose initial treatment was deemed adequate or probably adequate, and whose treatment for recurrent disease was conventional.
Interpretation: This study provides the most valid direct estimates yet available of the rate of progression from CIN3 to invasive cancer. Women with untreated CIN3 are at high risk of cervical cancer, whereas the risk is very low in women treated conventionally throughout.
Comment in
-
Heterogeneity in CIN3 diagnosis.Lancet Oncol. 2008 May;9(5):404-6. doi: 10.1016/S1470-2045(08)70110-4. Lancet Oncol. 2008. PMID: 18452848 No abstract available.
Similar articles
-
Consequences in women of participating in a study of the natural history of cervical intraepithelial neoplasia 3.Aust N Z J Obstet Gynaecol. 2010 Aug;50(4):363-70. doi: 10.1111/j.1479-828X.2010.01170.x. Aust N Z J Obstet Gynaecol. 2010. PMID: 20716265
-
Heterogeneity in CIN3 diagnosis.Lancet Oncol. 2008 May;9(5):404-6. doi: 10.1016/S1470-2045(08)70110-4. Lancet Oncol. 2008. PMID: 18452848 No abstract available.
-
Outcomes for women without conventional treatment for stage 1A (microinvasive) carcinoma of the cervix.Aust N Z J Obstet Gynaecol. 2018 Jun;58(3):321-329. doi: 10.1111/ajo.12753. Epub 2018 Feb 6. Aust N Z J Obstet Gynaecol. 2018. PMID: 29405269
-
Clinical presentation, treatment, and outcomes associated with vaginal intraepithelial neoplasia: A retrospective study of 118 patients.J Obstet Gynaecol Res. 2021 May;47(5):1624-1630. doi: 10.1111/jog.14733. Epub 2021 Mar 23. J Obstet Gynaecol Res. 2021. PMID: 33754436 Review.
-
[Management of CIN1].J Gynecol Obstet Biol Reprod (Paris). 2008 Feb;37 Suppl 1:S114-20. doi: 10.1016/j.jgyn.2007.11.017. Epub 2008 Jan 10. J Gynecol Obstet Biol Reprod (Paris). 2008. PMID: 18191500 Review. French.
Cited by
-
Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.BMJ. 2012 Nov 29;345:e7789. doi: 10.1136/bmj.e7789. BMJ. 2012. PMID: 23197596 Free PMC article. Clinical Trial.
-
Clinical investigation of the safety and efficacy of a cervical intraepithelial neoplasia treatment using a hyperthermia device that uses heat induced by alternating magnetic fields.Mol Clin Oncol. 2016 Aug;5(2):310-316. doi: 10.3892/mco.2016.929. Epub 2016 Jun 13. Mol Clin Oncol. 2016. PMID: 27446569 Free PMC article.
-
Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.BJOG. 2012 May;119(6):699-709. doi: 10.1111/j.1471-0528.2011.03228.x. Epub 2012 Jan 18. BJOG. 2012. PMID: 22251259 Free PMC article.
-
Multicentre Evaluation of Hepika Test Clinical Accuracy in Diagnosing HPV-Induced Cancer and Precancerous Lesions of the Uterine Cervix.Diagnostics (Basel). 2021 Mar 30;11(4):619. doi: 10.3390/diagnostics11040619. Diagnostics (Basel). 2021. PMID: 33808260 Free PMC article.
-
5-type HPV mRNA versus 14-type HPV DNA test: test performance, over-diagnosis and overtreatment in triage of women with minor cervical lesions.BMC Clin Pathol. 2016 Jun 7;16:9. doi: 10.1186/s12907-016-0032-x. eCollection 2016. BMC Clin Pathol. 2016. PMID: 27279798 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials